Kidney cancer. (Q40831882)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Kidney cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

24 September 2017

1 reference

Europe PubMed Central

Kidney cancer. (English)

1 reference

Europe PubMed Central

24 September 2017

author name string

N J Vogelzang

1

1 reference

Europe PubMed Central

24 September 2017

W M Stadler

2

1 reference

Europe PubMed Central

24 September 2017

language of work or name

0 references

publication date

1 November 1998

1 reference

Europe PubMed Central

24 September 2017

1 reference

Europe PubMed Central

24 September 2017

352

1 reference

Europe PubMed Central

24 September 2017

9141

1 reference

Europe PubMed Central

24 September 2017

1691-1696

1 reference

Europe PubMed Central

24 September 2017

Renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumour suppression by the human von Hippel-Lindau gene product

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Tissue microarrays for high-throughput molecular profiling of tumor specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Full speed ahead for tumor screening

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A Survey on Incidental Renal Cell Carcinoma in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

High incidence of papillary renal cell tumours in patients on chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Second cancer risk following testicular cancer: a follow-up study of 1,909 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiation induced renal cell cancer: a report of 4 cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Stage I renal cell carcinoma. A clinicopathologic study of 82 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The results of radical nephrectomy for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Resection of metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine: a phase II study in patients with advanced renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-2 toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy of metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Irreversible inactivation of interleukin 2 in a pump-based delivery environment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administrat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pronephric carcinoma: chromosomes of cells rescued from apoptosis by an oncogenic herpesvirus detected with a polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A new biological framework for cancer research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(98)01041-1

1 reference

Europe PubMed Central

24 September 2017

1 reference

Europe PubMed Central

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40831882&oldid=1507874969"